Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Anheuser-Busch Inbev SA (BUD) vs Novavax Inc (NVAX) Price & Performance

Anheuser-Busch Inbev SATrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Anheuser-Busch Inbev SA vs Novavax Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.31 (market cap $159.01B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Anheuser-Busch Inbev SA is far larger — about 121.4× Novavax Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

BUDNVAX
Market Cap
$159.01B$1.31B
Sector
Consumer StaplesHealth
52-Week High
$86.48$11.19
52-Week Low
$57.93$6.22
Enterprise Value
$223.42B$889.30M
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Anheuser-Busch Inbev SA

BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.

The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX